AUM is a clinical-stage biopharmaceutical company aiming to democratize R&D with a focus on discovering, acquiring, and developing novel therapeutics in oncology. The company holds exclusive worldwide rights in all disease indications for 2 first-in-class technologies with strong composition of matter patents in all major territories. 1) MNK Inhibition and 2) Multi-Kinase Inhibition (PIM/PI3K/mTOR). AUM utilizes a proprietary partnered AI-augmented platform to systematically discover and develop targeted cancer therapies focused on genetic targets. AUM's most advanced program is Phase II ready in colorectal cancer, and 2 additional pre-clinical programs have clear pathways to orphan drug designation. For 2 years in a row, the company has been awarded the Frost & Sullivan Asia-Pacific Biotech Entrepreneurial Company of the Year Award.